Imagion Biosystems (ASX:IBX) Ending Cash Position: A$1.85 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Imagion Biosystems Ending Cash Position?

Imagion Biosystems ASX:IBX +8.33% Ending Cash Position is A$1.85 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Imagion Biosystems's Ending Cash Position for the quarter that ended in Dec. 2025 was A$1.85 Mil.

Imagion Biosystems's quarterly Ending Cash Position declined from Dec. 2024 (A$2.67 Mil) to Jun. 2025 (A$0.88 Mil) but then increased from Jun. 2025 (A$0.88 Mil) to Dec. 2025 (A$1.85 Mil).

Imagion Biosystems's annual Ending Cash Position increased from Dec. 2023 (A$0.23 Mil) to Dec. 2024 (A$2.67 Mil) but then declined from Dec. 2024 (A$2.67 Mil) to Dec. 2025 (A$1.85 Mil).

Imagion Biosystems Ending Cash Position Related Terms

Imagion Biosystems Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Imagion Biosystems's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imagion Biosystems Ending Cash Position Chart

Imagion Biosystems Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 13.39 4.45 0.23 2.67 1.85

Imagion Biosystems Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.38 2.67 0.88 1.85

Imagion Biosystems Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Imagion Biosystems's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.671+-0.823
=1.85

Imagion Biosystems's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.126+-2.278
=1.85

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$1.85 Mil mean?
Imagion Biosystems (ASX:IBX) has a Ending Cash Position of A$1.85 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Imagion Biosystems and its competitors.
Is Imagion Biosystems' Ending Cash Position too high?
Imagion Biosystems' current Ending Cash Position is A$1.85 Mil.
How does Imagion Biosystems' Ending Cash Position compare to TMO and DHR?
Imagion Biosystems' Ending Cash Position of A$1.85 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Imagion Biosystems and its competitors. Imagion Biosystems's current Ending Cash Position is A$1.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 98.8% below its estimated fair value. The current Ending Cash Position is A$1.85 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current Ending Cash Position is A$1.85 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imagion Biosystems Business Description

Other Exchanges IBXXF:USA
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.